Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PBM
stocks logo

PBM

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Valuation Metrics

The current forward P/E ratio for Psyence Biomedical Ltd (PBM.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Psyence Biomedical Ltd 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

PBM News & Events

Events Timeline

(ET)
2025-11-25
07:14:10
Psyence Biomedical Launches Research Program on Psilocybin and Longevity
select
2025-11-20 (ET)
2025-11-20
07:05:51
Psyence Biomedical Secures Supply of High-Potency Iboga Bark
select
2025-11-12 (ET)
2025-11-12
07:22:35
Psyence Biomedical Launches Ibogaine Operations in Africa
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-21Benzinga
Intuit Shares Rise: 20 Stocks Making Moves in Premarket Trading

  • Intuit's Financial Performance: Intuit Inc. reported better-than-expected first-quarter results, with revenue of approximately $3.89 billion and adjusted earnings of $3.34 per share, leading to a 3.2% increase in share price during pre-market trading.

  • Second-Quarter Expectations: The company anticipates second-quarter revenue growth of 14% to 15% and adjusted earnings between $3.63 and $3.68 per share, which is below analyst estimates.

  • Pre-Market Stock Movements: Several stocks saw significant pre-market trading movements, including Nuvve Holding Corp, which surged 49.4%, and Enviri Corp, which gained 31.5% after announcing a major sale.

  • Declines in Other Stocks: Conversely, Pasithea Therapeutics Corp experienced a notable decline of 25.3% following the release of interim trial data, alongside other stocks like Safe & Green Holdings Corp and VisionSys AI Inc, which also saw significant drops.

[object Object]
Preview
9.0
11-20Newsfilter
Psyence BioMed Achieves Significant Milestone in Supplying Pharmaceutical-Grade Ibogaine for Global Clinical and Therapeutic Use

  • Sustainable Supply Chain: Psyence Biomedical Ltd. has established a sustainable supply of high-potency iboga bark through its partnership with PsyLabs, ensuring a reliable source of GMP-compliant ibogaine for clinical development targeting substance use disorders.

  • Ethical Sourcing Commitment: The collaboration emphasizes ethical sourcing and respect for cultural traditions, aiming to build a vertically integrated supply chain that supports both quality and sustainability in the production of ibogaine and related alkaloids.

  • Clinical Development Advancements: The company is advancing its ibogaine-based clinical programs, positioning itself as a leader in the emerging ibogaine sector, which is gaining international interest for its potential in addressing mental health needs.

  • Regulatory Compliance and Future Outlook: Psyence BioMed is focused on maintaining compliance with regulatory standards while navigating risks associated with drug development and market dynamics, emphasizing the need for rigorous scientific research and clinical trials.

[object Object]
Preview
4.5
09-23Benzinga
Super League Enterprise Shares Surge 200%; Check Out 20 Stocks Making Moves in Premarket Trading

  • Super League Enterprise Investment: Super League Enterprise, Inc. shares surged 200% to $9.83 in pre-market trading following a $10 million strategic equity investment from Evo Fund.

  • Other Notable Gainers: Several stocks saw significant pre-market gains, including Professional Diversity Network (up 88.8%), STRATA Skin Sciences (up 80%), and Jiuzi Holdings (up 50.9%).

  • Pre-Market Losers: Stocks like Psyence Biomedical and Diginex Limited experienced notable declines, with Psyence down 19.6% and Diginex down 17.7% in pre-market trading.

  • Market Overview: The article provides a snapshot of various stocks' performance in pre-market trading, highlighting both significant gainers and losers.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Psyence Biomedical Ltd (PBM) stock price today?

The current price of PBM is 1.81 USD — it has increased 1.69 % in the last trading day.

arrow icon

What is Psyence Biomedical Ltd (PBM)'s business?

Psyence Biomedical Ltd is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics. The Company is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. It is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.

arrow icon

What is the price predicton of PBM Stock?

Wall Street analysts forecast PBM stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PBM is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Psyence Biomedical Ltd (PBM)'s revenue for the last quarter?

Psyence Biomedical Ltd revenue for the last quarter amounts to -1.51M USD, increased 30.18 % YoY.

arrow icon

What is Psyence Biomedical Ltd (PBM)'s earnings per share (EPS) for the last quarter?

Psyence Biomedical Ltd. EPS for the last quarter amounts to -251456.00 USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Psyence Biomedical Ltd (PBM)'s fundamentals?

The market is revising No Change the revenue expectations for PBM for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -32.71%.
arrow icon

How many employees does Psyence Biomedical Ltd (PBM). have?

Psyence Biomedical Ltd (PBM) has 12 emplpoyees as of December 05 2025.

arrow icon

What is Psyence Biomedical Ltd (PBM) market cap?

Today PBM has the market capitalization of 3.39M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free